Cancer Family
Intestinal Neoplasm
CI-CAN-00000209Explore in graph →
Non-malignant1,893 active trials21 approved drugs383 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000209Explore in graph →
Clinical trials
9,158 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02921256 | Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer | completed | Phase 2 | 363 | National Cancer Institute (NCI)NIH | 2 | Dec 4, 2025 | clinicaltrials |
| NCT05358704 | Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer | suspended | Phase 2 | 38 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT03377361 | An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread(CheckMate 9N9) | completed | Phase 1 / Phase 2 | 325 | Bristol-Myers SquibbINDUSTRY | 10 | Dec 3, 2025 | clinicaltrials |
| NCT07261709 | Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial | not yet recruiting | Phase 2 | 236 | Sun Yat-sen UniversityOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05786716 | DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06333314 | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI(Pan-MSI-ACSE) | recruiting | Phase 2 | 120 | UNICANCEROTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07160647 | The Efficacy and Safety of Neoadjuvant Therapy With Iparomlimab and Tuvonralimab in Locally Advanced MSI-H/dMMR Colorectal Cancer: An Prospective, Single-Arm Study (Neo-IT)(Neo-IT) | active not recruiting | Phase 2 | 29 | Sir Run Run Shaw HospitalOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07230509 | Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate(NBCA) | recruiting | Phase 2 | 90 | Minia UniversityOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07257653 | The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer(concept) | recruiting | Phase 2 | 70 | Zhejiang UniversityOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07259590 | A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation | recruiting | Phase 1 / Phase 2 | 126 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07260058 | Immune Cell Therapy for Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 48 | Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.INDUSTRY | 0 | Dec 2, 2025 | clinicaltrials |
| NCT06154538 | Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer | recruiting | Phase 2 | 170 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT01147965 | QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA | completed | Phase 1 / Phase 2 | 43 | NantCell, Inc.INDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT06400160 | Clinical Trial of TB511 in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 12 | Twinpig Biolab, Inc.INDUSTRY | 0 | Nov 25, 2025 | clinicaltrials |
| NCT06493240 | Neoadjuvant Long-course Chemoradiotherapy Followed by Immunotherapy for Locally Advanced Mid-low Rectal Cancer(NLCCRIT-LARC) | completed | Phase 2 | 30 | Peking University People's HospitalOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07248020 | A Phase II Single-Arm Study of High-Bioavailability Curcumin as Neoadjuvant Chemoradiotherapy in Mid-to-Low Rectal Cancer: Integrated Clinical and Translational Analysis of Tumor Tissue(BCMRECRAD) | not yet recruiting | Phase 2 | 72 | Chang Gung Memorial HospitalOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05770102 | DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07243938 | Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET) | not yet recruiting | Phase 2 | 70 | Tao ZhangOTHER | 0 | Nov 24, 2025 | clinicaltrials |
| NCT07244705 | A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC | recruiting | Phase 1 / Phase 2 | 66 | Anbogen Therapeutics, Inc.INDUSTRY | 2 | Nov 24, 2025 | clinicaltrials |
| NCT02588651 | A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) | completed | Phase 2 | 23 | Deepa JagadeeshOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT07127497 | Clinical Study on the Safety and Relationship of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma | active not recruiting | Phase 2 | 50 | The First Affiliated Hospital of Anhui Medical UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT03926338 | Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer(PICC) | recruiting | Phase 2 | 270 | Sun Yat-sen UniversityOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT03984578 | Window of Opportunity Study in Colorectal Cancer | completed | Phase 2 | 33 | National Cancer Centre, SingaporeOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05748145 | Metronidazole as Preoperative Therapy in CRC / FusoMetro-001 | recruiting | Phase 2 | 40 | Oncology Institute of Southern SwitzerlandOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05945901 | A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer | active not recruiting | Phase 2 / Phase 3 | 669 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07233850 | A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers | not yet recruiting | Phase 2 | 300 | Shenyang Sunshine Pharmaceutical Co., LTD.INDUSTRY | 1 | Nov 18, 2025 | clinicaltrials |
| NCT01941641 | Colon Neoadjuvant FOLFOXIRI Study | active not recruiting | Phase 2 | 40 | Chinese University of Hong KongOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT03997435 | FOLFOXIRI With or Without Intensification for Rectal Cancer | active not recruiting | Phase 2 | 72 | CCTUOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05256381 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors | terminated | Phase 2 | 166 | SOTIO Biotech AGINDUSTRY | 9 | Nov 17, 2025 | clinicaltrials |
| NCT06640049 | A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China(China AZUR-1) | active not recruiting | Phase 2 | 23 | GlaxoSmithKlineINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT07106892 | Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer | recruiting | Phase 2 | 60 | Shanghai Henlius BiotechINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT07229872 | A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer That Has Failed Second-line or Above Treatment | not yet recruiting | Phase 2 | 18 | Harbin Medical UniversityOTHER | 0 | Nov 17, 2025 | clinicaltrials |
| NCT05194735 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors | terminated | Phase 1 / Phase 2 | 8 | Alaunos TherapeuticsINDUSTRY | 1 | Nov 10, 2025 | clinicaltrials |
| NCT07130903 | Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer | recruiting | Phase 2 | 102 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05169437 | Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors(PAVO) | terminated | Phase 2 | 22 | Tempus AIINDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT05205330 | Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers | active not recruiting | Phase 1 / Phase 2 | 107 | Rottapharm BiotechINDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT04208958 | Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer(ConsortiumIO) | completed | Phase 1 / Phase 2 | 56 | Vedanta Biosciences, Inc.INDUSTRY | 1 | Oct 27, 2025 | clinicaltrials |
| NCT05091346 | A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 89 | Eisai Inc.INDUSTRY | 4 | Oct 24, 2025 | clinicaltrials |
| NCT06557278 | Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer(COMUNITY) | withdrawn | Phase 2 | 0 | Mirror Biologics, Inc.INDUSTRY | 1 | Oct 21, 2025 | clinicaltrials |
| NCT04444622 | Immunotherapy for Third Line Metastatic Colorectal Cancer(STIMVAX) | completed | Phase 2 | 29 | Mirror Biologics, Inc.INDUSTRY | 1 | Oct 20, 2025 | clinicaltrials |
| NCT04660812 | An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.(ARC-9) | completed | Phase 1 / Phase 2 | 227 | Arcus Biosciences, Inc.INDUSTRY | 6 | Oct 20, 2025 | clinicaltrials |
| NCT05565417 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | active not recruiting | Phase 1 / Phase 2 | 67 | Immunitas TherapeuticsINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT05382442 | A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer | active not recruiting | Phase 2 | 254 | AkesoINDUSTRY | 2 | Oct 14, 2025 | clinicaltrials |
| NCT07215936 | Dose-dense Capecitabine Schedule [7days on _7 Days Off] in Colorectal Cancer in Comparison With Standered Regimen | active not recruiting | Phase 2 | 100 | Sohag UniversityOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT01312857 | Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer | completed | Phase 2 | 75 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT03184870 | A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 332 | Bristol-Myers SquibbINDUSTRY | 6 | Oct 9, 2025 | clinicaltrials |
| NCT07209384 | Clinical Efficacy of Transarterial Chemoembolization in Elderly Patients With Advanced Unresectable Colorectal Cancer | not yet recruiting | Phase 2 | 50 | Junpeng WangOTHER | 0 | Oct 7, 2025 | clinicaltrials |
| NCT06730100 | CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2025 | clinicaltrials |
| NCT05212012 | D,L-MEthadone and mFOLFOX6 in Treatment of Advanced Colorectal Cancer(MEFOX) | active not recruiting | Phase 1 / Phase 2 | 11 | AIO-Studien-gGmbHOTHER | 1 | Oct 3, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 4, 2025source: clinicaltrials